These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23012408)

  • 21. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
    Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
    PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells.
    Zhang X; Zhang X; Hu S; Zheng M; Zhang J; Zhao J; Zhang X; Yan B; Jia L; Zhao J; Wu K; Yang A; Zhang R
    Nucleic Acids Res; 2017 Jun; 45(10):5930-5944. PubMed ID: 28459998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.
    Tamura K; Wakimoto H; Agarwal AS; Rabkin SD; Bhere D; Martuza RL; Kuroda T; Kasmieh R; Shah K
    Mol Ther; 2013 Jan; 21(1):68-77. PubMed ID: 22929661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
    Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
    J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
    Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
    Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-homing cytotoxic human induced neural stem cells for cancer therapy.
    Bagó JR; Okolie O; Dumitru R; Ewend MG; Parker JS; Werff RV; Underhill TM; Schmid RS; Miller CR; Hingtgen SD
    Sci Transl Med; 2017 Feb; 9(375):. PubMed ID: 28148846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma.
    Li M; Mukasa A; Inda MM; Zhang J; Chin L; Cavenee W; Furnari F
    J Exp Med; 2011 Dec; 208(13):2657-73. PubMed ID: 22162832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
    Eller JL; Longo SL; Hicklin DJ; Canute GW
    Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles.
    Kaluzova M; Bouras A; Machaidze R; Hadjipanayis CG
    Oncotarget; 2015 Apr; 6(11):8788-806. PubMed ID: 25871395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.
    Maussang D; Mujić-Delić A; Descamps FJ; Stortelers C; Vanlandschoot P; Stigter-van Walsum M; Vischer HF; van Roy M; Vosjan M; Gonzalez-Pajuelo M; van Dongen GA; Merchiers P; van Rompaey P; Smit MJ
    J Biol Chem; 2013 Oct; 288(41):29562-72. PubMed ID: 23979133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
    Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
    J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
    Pozo N; Zahonero C; Fernández P; Liñares JM; Ayuso A; Hagiwara M; Pérez A; Ricoy JR; Hernández-Laín A; Sepúlveda JM; Sánchez-Gómez P
    J Clin Invest; 2013 Jun; 123(6):2475-87. PubMed ID: 23635774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model.
    Andreou T; Williams J; Brownlie RJ; Salmond RJ; Watson E; Shaw G; Melcher A; Wurdak H; Short SC; Lorger M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
    Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
    Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma.
    Agliardi G; Liuzzi AR; Hotblack A; De Feo D; Núñez N; Stowe CL; Friebel E; Nannini F; Rindlisbacher L; Roberts TA; Ramasawmy R; Williams IP; Siow BM; Lythgoe MF; Kalber TL; Quezada SA; Pule MA; Tugues S; Straathof K; Becher B
    Nat Commun; 2021 Jan; 12(1):444. PubMed ID: 33469002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
    Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
    Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploiting tumor-intrinsic signals to induce mesenchymal stem cell-mediated suicide gene therapy to fight malignant glioma.
    Li M; Sun S; Dangelmajer S; Zhang Q; Wang J; Hu F; Dong F; Kahlert UD; Zhu M; Lei T
    Stem Cell Res Ther; 2019 Mar; 10(1):88. PubMed ID: 30867058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
    Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
    Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
    Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
    Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.